ONCOLOGY BIOSIMILARS MARKET ANALYSIS

Oncology Biosimilars MarketSize and Trends

There was about a decade gap in approval of first biosimilars in two key markets, Europe and the U.S. First biosimilar was approved in 2006 in Europe, however, in the U.S. first product was approved in 2015. But since approving the first biosimilar, the FDA has approved five products in 2017. Out of these five biosimilars, two were approved for oncology. First, oncology biosimilar Mvasi (bevacizumab-awwb) received approval in September 2017, and second one, Ogivri (trastuzumab) was approved in December 2017. In Europe, both of the products have been approved, and Mvasi received approval from European Commission in January 2018.

Moreover, there are number of biosimilar application pending in the U.S. and Europe. For Herceptin (trastuzumab) alone, there are around four application pending in the FDA. These four application are from Amgen and Allergan, Celltrion and Teva, Pfizer, and Samsung Bioepis. Recent approval of products, and potential approval in next few years is expected to boost the market growth over the forecast period.

Oncology Biosimilars Market Taxonomy

By Cancer Type:

• Lung Cancer
• Colorectal cancer
• Cervical Cancer
• Breast Cancer
• Kidney cancer
• Stomach cancer
• Brain Cancer
• Others

By Product Type:

• Monoclonal Antibody
• Immunomodulators
• Others

By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies